For more than 20 years since its establishment, Jiuzhang Biotech has been committed to the development of such projects as “the research and development of national class I and II new anti-tumor drugs with independent intellectual property” and “the development of natural plant-based healthcare food by incorporating the nanotechnology”, and has invested hundreds of millions of scientific research funds in succession. During the process, Jiuzhang Biotech has reaped many honors:
In 2004
The “High-purity Plant Monomer Project” was listed as the torch project by Science and Technology Department of Sichuan Province.
In 2005
The “High-purity Plant Monomer Project” had listed as the national torch project by Ministry of Science and Technology of the People's Republic of China;
“The research on anticancer mechanism and application development of new anti-tumor drug-plant monomer molecule” had been listed in the pilot project of national science and technology innovation by Sichuan Provincial Development and Reform Commission.
In 2006
“Preclinical Study on High Purity Plant Monomer and its Preparation” had been listed as key scientific and technological research projects in Sichuan Province;
“Preclinical Study on High Purity Plant Monomer and its Preparation” had been listed as the key scientific and technological innovation project in high-tech district of Chengdu.
In 2007
“The Research and Development of a Class I New Drug Monomer and its Injection for Treating Lung Cancer” had been listed as Industrial Technology Research and Development Project by Sichuan Province Development and Reform Commission;
“The Research on Anticancer Mechanism and Further Application Development of Plant Monomer Molecule” had been listed as the key project of technology innovation in Sichuan province in 2007 by Sichuan Province Economic and Information Department.
In 2008
“The Class I New Drug Monomer and its Injection for Treating Lung Cancer” are listed as the Chengdu High-tech Area Innovation Fund Project;
The project “a Class I new drug--drug substance and monomer lyophilized powder injection” was listed as” the seventh China Scientist Forum's most valuable investment item”.
In 2009
“A class I new drug monomer and its injections for treating lung cancer” was listed as the innovation project of SME's Technology Innovation Fund by Ministry of Science and Technology of the People's Republic of China;
“The Preclinical Study of A class I new drug substance and its injection for treating lung cancer” had been listed as the project of science and technology support program by Science and Technology Department of Sichuan Province;
The company was listed as the key cultivation enterprise in the development plan of biomedical industry in Chengdu and the drug substance and its preparations are listed as the key products.
In 2010
It was listed by the Ministry of Industry and Information Technology of People's Republic of China as a major national science and technology achievements transformation project in 2010.
In 2011
It had been listed by Chengdu Science and Technology Bureau as a key scientific and technological project of Chengdu City.
In 2012
It had been listed as an independent innovation project by Chengdu Science and Technology Bureau.
In 2013
It had been listed as a special project of transformation of scientific and technological achievements by Science and Technology Department of Sichuan Province and High-tech Zone.
In 2016
Phase I/II Clinical Study of Chlorogenic Acid for Injection, the Class I of the New Medicines had been listed by National Health and Family Planning Commission of PRC and Ministry of Science and Technology of the People's Republic of China in the National 13th-five-year plan Science and Technology Major Special Major New Drug Creation Project;
Nature, as the world famous science journal, had conducted an exclusive interview to Mr. Zhang Jie, the inventor of chlorogenic acid, Professor Chen Xiaoguang from the Institute of Materia Medica, China Academy of Medical Sciences, the study director of the anti-tumor mechanism research, and Professor Li Wenbin from the Department of Brain Glioma at the Beijing Shijitan Hospital (currently in the Beijing Tiantan Hospital affiliated to the Capital Medical University), the principal investigator of the glioma clinical trial in the “1st Pharmaceutical Investment and Innovation Conference”, and had published the interview content in the English version of Nature issued on December 22, 2016, entitled as New Breakthrough in Antitumor Drug.
In 2017
“Phase II clinical study on the treatment of glioma with chlorogenic acid for injection, class I of the innovative natural small molecule immune drug” was appraised as “a major special project in Sichuan Province” by Sichuan Science and Technology Department;
Scientific Reports, a journal of Nature, published an article entitled Chlorogenic Acid Inhibits Glioblastoma Growth through Repolarizating Macrophage from M2 to M1 Phenotype, which elaborated and demonstrated the mechanism of chlorogenic acid for injection promoting apoptosis and inhibiting growth of malignant tumors. Great external repercussions have been achieved.
In 2018
Research and Development of Chlorogenic Acid for Injection (Phase Ib Clinical Study of Advanced Lung Cancer) obtained the Directional Financial Transfer Payment Project in Sichuan Province.
In 2021
"Phase II/III Clinical Study of Chlorogenic Acid for Injection, a New Class 1 Drug for Malignant Glioma" won the title of 2020 Major Science and Technology Innovation Project of Chengdu Science and Technology Bureau.
